Mimedx Group, Inc · NASDAQ:MDXG
Mimedx — Corporate Update (June 2023)
11 slides from Mimedx's corporate update, Jun 20, 2023
Slide 1: Helping Humans Heal Investor Conference Call
HELPING HUMANS HEAL Investor Conference Call June 20, 2023 Exhibit 99.2
Slide 2: Disclaimer & Cautionary Statements
2 Disclaimer & Cautionary Statements Some of the information and statements contained in this presentation and certain oral statements made from time to time by representatives of MIMEDX constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 199
Slide 3: Disclaimer & Cautionary Statements (cont.)
3 Disclaimer & Cautionary Statements (cont.) Additional forward-looking statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations. Forward-looking state
Slide 4: Use of Non-GAAP Financial Measures
4 Use of Non-GAAP Financial Measures • In addition to our results in accordance with generally accepted accounting principles (“GAAP”), we provide certain non-GAAP metrics including Earnings Before Interest, Taxes, Depreciation and Amortization (“EBITDA”), Adjusted EBITDA, and related margins. • We
Slide 5: Announcing Strategic Realignment
5 Announcing Strategic Realignment Increasing Focus on Wound & Surgical Business Suspending Knee Osteoarthritis (‘KOA’) Program & Disbanding Regenerative Medicine Business Unit Discussing Long Range Financial Targets Realignment sharpens our focus on our core Wound & Surgical end markets as we look
Slide 6: MIMEDX: Focused on Global Leadership in Healing Solutions
6 MIMEDX: Focused on Global Leadership in Healing Solutions #1 Amniotic Skin Substitute* Over 300,000,000 Payer Covered Lives Best-in-Class Wound Product Portfolio Expanding Offering for Surgical Market 15 >15 Years Dedicated to Innovation in Wound Care Unparalleled Expertise Targeted International
Slide 7: Introducing Our New 'Why' Statement & Company Vision
7 Introducing Our New ‘Why’ Statement & Company Vision Our Why: Our Vision: Helping Humans Heal To be the leading global provider of healing solutions through relentless innovation to restore quality of life
Slide 8: Suspending KOA and Disbanding Regenerative Medicine Business Unit
8 Suspending KOA Disbanding Regenerative Medicine business unit and eliminating clinical trial costs and associated expense Simplifies & focuses the Company on winning in the marketplace today Aligning resources in order to accelerate commercial success in Wound & Surgical Impact Expect to generate
Slide 9: Sizable Opportunities in End Markets
9 Sizable Opportunities in Wound & Surgical End Markets $1.1B $1.5B $0.9B $1.3B$0.5B $0.7B MIMEDX 2022 Net Sales 2022 2026E U.S. Wound U.S. Surgical Japan $2.5B $3.5B $268MM *CAGRs are the estimated cumulative annual growth rates for the period January 1, 2022 through December 31, 2026 BioMed GPS Sm
Slide 10: Targeting Above Market Growth & Improving Financial Profile
10 Targeting Above Market Growth & Improving Financial Profile In the long term, expect to deliver low double-digit percentage net sales growth on an annual basis With strong start to year, anticipating 2023 full year net sales growth percentage to be higher - in the mid-teens On a pro-forma basis,
Slide 11: Our Strategic Priorities Remain
11 Our Strategic Priorities Remain Build leadership position in Wound & Surgical Develop opportunities in adjacent markets Demonstrate corporate discipline around expenses • Grow in all sites-of-service • Regain share in private physician office • Go deeper and wider in Surgical Recovery • Invest or